Transaction

African Development Bank Group invests USD 15 million in Biologicals and Vaccines Institute's (Biovac) operations in South Africa

Announced
5 August 2026
Target
The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited
Value
$15m
Asset class
Private Credit
Type
Debt Financing
Instrument
Private Capital (Debt)
Lead investors
The African Development Bank Group (AfDB)
Investors
The African Development Bank Group (AfDB)
Sector
Healthcare / Biotechnology, Pharmaceuticals
Markets
Lesotho, Angola, Eswatini, Namibia, Botswana, Mozambique, South Africa

About the target

The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, trading as The Biovac Institute, is a South African biopharmaceutical company based in Pinelands, Cape Town, South Africa. Established in 2003 as a public-private partnership between the South African government and a private consortium, Biovac was created to rebuild South Africa's human vaccine manufacturing capacity following the cessation of vaccine production at the State Vaccine Institute. The company is involved in vaccine development and manufacturing, including upstream and downstream processing, formulation, fill-and-finish manufacturing, labelling and packaging, quality control, distribution and cold-chain logistics. It has entered into technology-transfer partnerships and agreements with international vaccine manufacturers, including Sanofi, Pfizer, EuBiologics, and Biological E. Biovac supplies vaccines in South Africa and other Southern African markets, including Angola, Botswana, Eswatini, Lesotho, Mozambique, and Namibia.

Sources

  1. empowerafrica.com
  2. Partner Researchers